Mydecine Competitors

Pink Sheets . USA . 
Stock . Mydecine Innovations Group
MYCOF Stock  USD 0.01  0  28.57%   
Analyzing Mydecine Innovations competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Mydecine Innovations to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Mydecine Innovations Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Mydecine Innovations competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.0142.89
Details
Intrinsic
Valuation
LowRealHigh
0.00042.88
Details
Naive
Forecast
LowNextHigh
0.00010.0142.89
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
00.010.01
Details

Mydecine Innovations Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mydecine Innovations and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Mydecine and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mydecine Innovations does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
AQSZF
+ 0.63
CBDNF
AQSZF
+ 0.57
MGCLF
MGCLF
+ 0.54
CBDNF
FLHLF
+ 0.36
MGCLF
FLHLF
+ 0.35
AQSZF
CBDNF
+ 0.32
CNNA
  
High negative correlations   
MGCLF
- 0.14
GXXY
MGCLF
- 0.14
GRCU
CBDNF
- 0.13
GRCU
CBDY
- 0.11
MGCLF
CBDY
- 0.11
CBDNF
GXXY
- 0.11
RMRK

Risk-Adjusted Indicators

There is a big difference between Mydecine Pink Sheet performing well and Mydecine Innovations Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mydecine Innovations' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
GRCU  37.92  10.96  0.20 (3.51) 25.99 
(100.00)
 100.00 
(50.00)
 150.00 
CNNA  7.09  0.00  0.01  0.12  10.47 
(14.93)
 20.00 
(24.00)
 89.44 
RMRK  8.78  1.20  0.04 (1.94) 9.96 
(33.33)
 33.33 
(25.00)
 58.33 
GXXY  3.20 (0.29) 0.00 (0.29) 0.00 
 0.00 
 12.97 
(18.69)
 67.08 
INQD  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CBDNF  3.63 (0.03) 0.00  0.14  0.00 
 0.00 
 14.75 
(13.33)
 47.67 
MGCLF  1.17 (0.41) 0.00 (1.77) 0.00 
 0.00 
 0.00 
(3.70)
 29.91 
CBDY  10.96  1.57  0.07 (2.32) 12.10 
(16.57)
 38.10 
(25.00)
 83.33 
AQSZF  2.82 (1.12) 0.00 (0.61) 0.00 
 0.00 
 2.22 
(10.64)
 45.35 
FLHLF  11.61  0.91  0.05  6.11  13.07 
(16.23)
 27.08 
(24.77)
 91.17 
All Fundamental Data

Mydecine Innovations Competitive Analysis

The better you understand Mydecine Innovations competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mydecine Innovations' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mydecine Innovations' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MYCOF GRCU CNNA RMRK GXXY INQD CBDNF MGCLF CBDY AQSZF
 28.57 
 0.01 
Mydecine
 50.00 
 0.0001 
Green
 3.12 
 0 
Cann
 25.00 
 0.0003 
Rimrock
 18.38 
 0.02 
Galexxy
 0.00 
 0.0001 
Indoor
 0.00 
 0.06 
CBD
 0.00 
 0.21 
MGC
 20.00 
 0 
Target
 7.04 
 0.01 
Aequus
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Out of control
Out of control
Out of control
Very steady
Very steady
Very steady
Out of control
Out of control
Market Performance
(90 Days Performance)
Good
Good
Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Modest
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Quite High
Very High
Very High
Quite High
About Average
Dangerous
Dangerous
Above Average
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Not Rated
Strong Sell
Strong Sell
Current Ratio
1.26
4.85
20.16
0.01
0.17
3.09
0.09
0.84
0.17
0.78
Net Asset
7.58 M
406
N/A
396.96 K
N/A
3.08 K
2.09 M
22.6 M
13.06 M
4.35 M
Profit Margin
N/A
4.96
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-1.36
EBITDA
(23.14 M)
861.7 K
(275.98 K)
(452.96 K)
N/A
(45.75 M)
(4.6 M)
(16.44 M)
2.23 M
(1.23 M)
Current Valuation
8.64 M
4.85 M
48
369.24 K
N/A
15.71 M
14.44 M
24.97 M
4.2 M
3.03 M
Price To Book
23.41
N/A
7.0E-4
7.41
N/A
43.0
N/A
5.69
7.83
32.78
Operating Margin
N/A
0.62
-21.26
N/A
-8.06
N/A
-2.71
-3.28
N/A
-1.31
Retained Earnings
N/A
(1.58 M)
(4 M)
(4.47 M)
N/A
(10.89 M)
N/A
N/A
N/A
(5.72 M)
Current Asset
N/A
N/A
N/A
5 K
N/A
44 K
N/A
N/A
N/A
458 K
Beta
3.42
1.09
1.21
1.01
1.73
3.47
0.49
1.23
-0.51
0.44
Number Of Employees
11
20
1
2
2
2
2
16
61
14
Shares Outstanding
13.01 M
N/A
4.44 K
780.76 M
N/A
2.69 B
49.46 M
2.87 B
617.03 M
132.63 M
Cash Flow From Operations
(24.05 M)
(73.09 K)
(244.54 K)
(284.62 K)
(96.96 K)
(17.45 K)
(1.14 M)
(12.16 M)
100.12 K
(1.17 M)
Total Debt
4.35 M
3.1 M
N/A
N/A
523.03 K
24.44 K
1.34 M
4.35 M
1.72 M
26.09 K
Return On Equity
-12.24
0.55
-2.6
-14.25
N/A
N/A
N/A
-2.19
-23.05
-2.92
Z Score
-9.3
-22.03
-12.6
-19.9
N/A
N/A
-4.2
1.8
0.6
93.4
Return On Asset
-1.76
0.023
-0.85
-0.69
-1.94
-7.24
-1.38
-0.45
-0.0596
-0.42
Book Value Per Share
-0.36
-2.23
0.001
N/A
-0.007
N/A
-0.26
0.002
-0.005
-0.003
Current Liabilities
N/A
539 K
384 K
434 K
N/A
488 K
N/A
N/A
N/A
704 K
Total Asset
7.58 M
406
417 K
396.96 K
N/A
3.08 K
2.09 M
22.6 M
13.06 M
4.35 M
Debt To Equity
0.057
0.091
0.14
1.08
N/A
40.8
N/A
0.84
1.82
1.39
Target Price
140.0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
N/A
N/A
6.12
N/A
N/A
Market Capitalization
5.94 M
2.54 M
421
312.3 K
N/A
15.6 M
5.93 M
17.2 M
2.47 M
4.12 M
Price To Earning
N/A
N/A
N/A
-0.08
N/A
0.23
N/A
N/A
N/A
-1.79
Price To Sales
677.59
2.8
0.0306
N/A
N/A
22.37
2.79
5.81
340.13
1.44
Net Income
(28.9 M)
(1.09 M)
(249.82 K)
(851.33 K)
(161.23 K)
(46.28 M)
(5.25 M)
(20.35 M)
272.88 K
(1.81 M)
Earnings Per Share
-4.68
3.15
-0.001
-0.012
-0.003
0.03
-0.11
-0.005
N/A
-0.01
Shares Owned By Insiders
8.71
N/A
9.5
N/A
N/A
0.12
26.61
9.1
11.37
14.96
Revenue
7.49 K
13.17 K
13.23 K
N/A
20 K
N/A
166.95 K
4.65 M
N/A
2.71 M
Working Capital
N/A
(539 K)
(384 K)
(429 K)
N/A
(444 K)
N/A
N/A
N/A
(246 K)
Cash And Equivalents
324.15 K
80 K
59.87 K
2.22 K
97.74 K
191.87 K
59.92 K
1.89 M
114.21 K
1.39 M
Cash Per Share
0.04
0.04
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.01
Gross Profit
7.49 K
989.6 K
16.71 K
(161.9 K)
N/A
N/A
3.61 K
562.87 K
5 K
2.69 M
Day Typical Price
0.005
1.0E-4
0.003
3.0E-4
0.0161
1.0E-4
0.06
0.21
0.0024
0.0063
Accumulation Distribution
N/A
0.5
0.24
N/A
N/A
N/A
N/A
N/A
N/A
0.42
Market Facilitation Index
N/A
1.0E-4
8.0E-4
N/A
N/A
N/A
N/A
N/A
N/A
0.0032
Daily Balance Of Power
(9,223,372,036,855)
(1.00)
0.125
(9,223,372,036,855)
9.2 T
0.0
0.0
0.0
9.2 T
(0.16)
Period Momentum Indicator
(0)
(0.0001)
1.0E-4
(0.0001)
0.0025
N/A
N/A
N/A
4.0E-4
(0.0005)
Rate Of Daily Change
0.71
0.5
1.03
0.75
1.18
1.0
1.0
1.0
1.2
0.93
Day Median Price
0.005
1.0E-4
0.0029
3.0E-4
0.0161
1.0E-4
0.06
0.21
0.0024
0.0061
Price Action Indicator
(0)
(0.0001)
5.0E-4
(0.00005)
0.0013
N/A
N/A
N/A
2.0E-4
3.0E-4
Relative Strength Index
60.07
64.05
58.2
31.38
5.97
N/A
69.22
0.0117
69.68
90.17
Coefficient Of Variation
576.02
478.73
4437.36
1360.66
(4,632)
N/A
(2,499)
(865.51)
1072.78
(744.88)
Mean Deviation
31.11
37.92
7.09
8.78
3.2
N/A
3.63
1.17
10.96
2.82
Jensen Alpha
6.67
10.96
0.001
1.2
(0.29)
N/A
(0.03)
(0.41)
1.57
(1.12)
Total Risk Alpha
0.6806
2.6
(1.85)
(1.31)
(1.60)
N/A
(1.40)
(0.90)
(1.05)
(2.01)
Sortino Ratio
0.1886
0.2019
0.0099
0.0379
N/A
N/A
N/A
N/A
0.0728
N/A
Downside Variance
1500.5
2692.31
316.63
703.13
N/A
N/A
N/A
N/A
356.58
N/A
Standard Deviation
42.84
50.77
13.61
15.46
8.87
N/A
7.02
3.26
16.15
6.87
Kurtosis
1.64
(0.39)
5.86
0.9513
8.25
N/A
4.24
32.44
1.63
25.6
Potential Upside
100.0
100.0
20.0
33.33
12.97
N/A
14.75
N/A
38.1
2.22
Treynor Ratio
1.19
(3.51)
0.1212
(1.94)
(0.29)
N/A
0.1371
(1.77)
(2.32)
(0.61)
Maximum Drawdown
198.41
150.0
89.44
58.33
67.08
N/A
47.67
29.91
83.33
45.35
Variance
1835.42
2578.09
185.23
239.07
78.6
N/A
49.28
10.6
260.81
47.14
Market Risk Adjusted Performance
1.2
(3.50)
0.1312
(1.93)
(0.28)
N/A
0.1471
(1.76)
(2.31)
(0.60)
Risk Adjusted Performance
0.143
0.17
0.0267
0.0659
(0.01)
N/A
(0.02)
(0.08)
0.081
(0.09)
Skewness
1.12
0.8289
0.4909
0.5993
(0.06)
N/A
0.1487
(4.78)
0.6998
(3.66)
Semi Deviation
25.03
25.99
10.47
9.96
N/A
N/A
N/A
N/A
12.1
N/A
Information Ratio
0.1706
0.2063
0.0129
0.065
(0.04)
N/A
(0.06)
(0.16)
0.0851
(0.15)
Value At Risk
(50.00)
(50.00)
(24.00)
(25.00)
(18.69)
N/A
(13.33)
(3.70)
(25.00)
(10.64)
Expected Short fall
(53.81)
(100.00)
(14.93)
(33.33)
N/A
N/A
N/A
N/A
(16.57)
N/A
Downside Deviation
38.74
51.89
17.79
26.52
N/A
N/A
N/A
N/A
18.88
N/A
Semi Variance
626.75
675.46
109.54
99.29
N/A
N/A
N/A
N/A
146.31
N/A

Mydecine Innovations Competition Performance Charts

Five steps to successful analysis of Mydecine Innovations Competition

Mydecine Innovations' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mydecine Innovations in relation to its competition. Mydecine Innovations' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Mydecine Innovations in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mydecine Innovations' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mydecine Innovations, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Mydecine Innovations position

In addition to having Mydecine Innovations in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cannabis Thematic Idea Now

Cannabis
Cannabis Theme
Equities that are involved in production and delivery of legal cannabis. This theme is designed for investors that are willing to accept higher levels of market risk inherited by cannabis production and distribution globally. The Cannabis theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cannabis Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Mydecine Pink Sheet

Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY